Last updated: March 2026
Methylstenbolone (M-Sten) is a 17α-alkylated oral designer steroid structurally related to Superdrol, marketed as a legal prohormone until its Schedule III classification under DASCA 2014. It produces dry, lean muscle gains with significant hepatotoxicity and virtually no clinical research — harm reduction relies on anecdotal community data.
M-Sten's anabolic effects come from direct androgen receptor activation. Its oral bioavailability is achieved via 17α-methylation — the same modification responsible for its hepatotoxicity.
Methylstenbolone directly binds and activates androgen receptors in muscle tissue, skeletal muscle, and other androgenic tissues. Unlike prohormones that require conversion to an active metabolite, M-Sten is itself the active compound. Its receptor binding affinity is estimated to be high relative to testosterone, producing strong anabolic effects at low milligram doses. This is why community doses are typically kept to 10–20mg/day — a very small amount by mass.
The 17α-methyl group on M-Sten's structure prevents first-pass liver metabolism, allowing the compound to enter systemic circulation orally. This modification is also directly responsible for hepatotoxicity. The liver must process and break down 17α-alkylated compounds via pathways that generate oxidative stress and can cause cholestasis (bile flow obstruction), elevated transaminases (ALT/AST), and in extreme cases, peliosis hepatis. Cycle length is strictly limited in community practice for this reason.
M-Sten does not aromatize to estradiol, meaning it produces no estrogen-related water retention. Users consistently report very dry, dense muscle gains — similar to Superdrol — without the bloat seen with compounds like testosterone or Dianabol. The lack of estrogenic activity also means no gynecomastia risk from M-Sten itself. However, this also removes any cardiovascular protection that estrogen provides, contributing to adverse lipid effects.
Like all anabolic androgens, methylstenbolone suppresses the hypothalamic-pituitary-testicular axis (HPTA) by signaling the hypothalamus to reduce GnRH pulsatility, which in turn reduces LH and FSH secretion from the pituitary. This leads to near-complete shutdown of endogenous testosterone production during the cycle. Post-cycle therapy (PCT) with SERMs (tamoxifen or clomiphene) is considered essential in harm-reduction practice to restore HPTA function after cycle completion.
No human clinical trials exist for methylstenbolone. All data below reflects community-sourced anecdotal reports and in vitro structural analysis. Source quality is explicitly noted.
Liver monitoring and hepatoprotective support are the highest priority harm-reduction practices for any 17α-alkylated oral compound.
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
This page is for educational and harm-reduction purposes only. Methylstenbolone is a Schedule III controlled substance in the United States under the Designer Anabolic Steroid Control Act (DASCA) of 2014. Possession, sale, or distribution without a valid prescription is a federal crime. No human clinical trials exist for this compound. All human data on this page is derived from anecdotal community reports and should not be interpreted as established medical fact. This content does not constitute medical advice. Always consult a licensed physician before using any anabolic agent.